Orphan Antibiotics? Woodcock Says It May Be Possible If IDSA’s New Pathway Is Implemented
This article was originally published in The Pink Sheet Daily
CDER director says SPLMU proposal could open up antibiotics for resistant pathogens to orphan drug incentives, which could help prime the anemic development pipeline.
You may also be interested in...
LPAD Approval Pathway Is Not Saving Antimicrobial Development
US FDA and CMS explore reimbursement ideas to strengthen business case for antimicrobial development; new approval pathway likely is only needed in special situations.
Antibiotic Guidance: Limited Populations Do Not Include Rare Infections
US FDA draft guidance on Limited Population Antibacterial Drug pathway says eligibility considerations for preventative products will center on size of population receiving drug, not incidence of infection.
Ebola Treatments Could Be Orphan Candidates – But Vaccines, Probably Not
FDA expects few people would get the disease in the U.S., but many could receive a vaccine.